Follicular Lymphoma | Tumor

FDA Approves Epkinly for Relapsed, Refractory Follicular Lymphoma

June 27th 2024, 12:09am

Article

The Food and Drug Administration approved Epkinly, a bispecific T-cell engager, for certain patients with follicular lymphoma.

Advice from an Oncologist After a Cancer Diagnosis

June 6th 2024, 5:00pm

Article

When I came across an article with advice written by an oncologist for patients, I thought about his advice carefully.

My Interesting Cancer Advocacy Group

May 29th 2024, 5:00pm

Article

As someone with follicular lymphoma, I joined a cancer advocacy group, but it wasn't what I was expecting.

FDA Approves Breyanzi for Relapsed, Refractory Follicular Lymphoma

May 15th 2024, 8:55pm

Article

The Food and Drug Administration approved Breyanzi for patients with pretreated, relapsed or refractory follicular lymphoma.

Validating My Feelings During Cancer

May 10th 2024, 5:00pm

Article

When people try to cheer me up when I feel a certain way towards my cancer, it makes me feel like my feelings aren't valid.

When My Wait and Watch Routine for Follicular Lymphoma Ended

April 29th 2024, 9:00pm

Article

I reflected upon my last great trip with my husband and the moment my wait and watch approach ended for my follicular lymphoma.

Finding Cancer Cures at Any and All Costs

April 9th 2024, 5:00pm

Article

It was disconcerting to me when my oncologist was unsure about the treatment he was giving me and knew what the next would be without giving the first a chance.

No More Lymphoma

March 27th 2024, 1:07pm

Article

For the Jewish New Year, I had no more signs of lymphoma.

I’ve Had Enough Scans to Know How They Taste

March 25th 2024, 1:00pm

Article

Even the difficult experiences that we share, like the emotional and physical discomfort that comes with a cancer scan, can be a little easier when we know someone else has been through them, too.

‘Another Option Available’ for Treatment in Follicular Lymphoma

March 20th 2024, 3:04pm

Article

Treatment with Brukinsa and Gazyva poses a new option for certain patients with follicular lymphoma, with tolerable side effects, an expert told CURE®.